Margalit B. Mokyr - Concepedia

Author

Margalit B. Mokyr

Also Known As

M B Mokyr, M. B. Mokyr, M.B. Mokyr, MARGALIT BIRNBAUM MOKYR, Main, Margalit B Mokyr, Margalit B. Mokyr, Margalit Birnbaum Mokyr, Margalit Mokyr, MargalitB. Mokyr

Publications

Citations

H-Index

Concepts

All Affiliations

University of Illinois Chicago University of Chicago May Institute Yale University

About

Margalit B. Mokyr is an author at University of Illinois Chicago specializing in immunotherapy, immunology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	42	1.6K
2	Cell Biology	19	30	979
3	Health Sciences	2	2	102
4	Allergy	1	1	40
5	Cellular Therapies	1	1	19

Margalit B. Mokyr

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Margalit B. Mokyr, T. V. Kalinichenko, L Gorelik, PubMed Therapeutic PotentialChemotherapeutic Agent MelphalanImmunologyImmunoeditingPharmacotherapy	1998	130
Activation of suppressor T cells by tumour cells and specific antibody Richard K. Gershon, Margalit B. Mokyr, Malcolm S. Mitchell Nature Tumor ImmunologyCancer ImmunosurveillanceT-regulatory CellImmunologyTumor Immunity	1974	118
Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. James C. D. Hengst, Margalit B. Mokyr, Sheldon Dray PubMed ImmunologyImmunoeditingMetronomic ChemotherapyImmunotherapyTumor Challenge	1981	100
Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression. Vladimir V. Kalinichenko, Margalit B. Mokyr, Lloyd H. Graf, PubMed T-regulatory CellImmunologyImmune RegulationImmunologic MechanismSpleen Cells	1999	92
Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. James C. D. Hengst, Margalit B. Mokyr, Sheldon Dray PubMed Mopc-315 Tumor-bearing MiceImmunologyImmunotherapeuticsSpleen CellsImmunotherapy	1980	92
Norepinephrine-Mediated Inhibition of Antitumor Cytotoxic T Lymphocyte Generation Involves a β-Adrenergic Receptor Mechanism and Decreased TNF-α Gene Expression Vladimir V. Kalinichenko, Margalit B. Mokyr, Lloyd H. Graf, The Journal of Immunology ImmunologyImmune RegulationImmunoeditingImmunologic MechanismImmunotherapeutics	1999	83
On the Mode of Action of BCG M S Mitchell, Dahlia Kirkpatrick, Margalit B. Mokyr, Nature New Biology Mathematical Modelling	1973	81
Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors. Margalit B. Mokyr, James C. D. Hengst, Sheldon Dray PubMed Cyclophosphamide-induced RejectionImmune Spleen CellsImmunologyImmunoeditingAntitumor Immunity	1982	59
Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide. Margalit B. Mokyr, Sheldon Dray PubMed Low DoseImmunologyImmunoeditingPathologySpleen Cells	1983	59
Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth Shlomo Ben‐Efraim, Robert C. Bocian, Margalit B. Mokyr, Cancer Immunology Immunotherapy Melphalan TherapyMedicineMalignant Blood DisorderPathologyImmune Checkpoint Inhibitor	1983	58

Page 1